- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06162650
Total Neoadjuvant Therapy in Rectal Cancer
December 7, 2023 updated by: Yu-Min Yeh, National Cheng-Kung University Hospital
A Phase II Study of Total Neoadjuvant Therapy in Rectal Cancer
In this phase 2 study, the efficacy of total neoadjuvant therapy in Taiwanese patients with rectal cancer will be investigated.
Patients with stage II or III middle/low rectal cancer will be prospective enrolled.
The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered.
The primary endpoint is the complete response (CR) rate which will take into account the patients with clinical and pathological complete response.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Detailed Description
This is a single center, single-arm, open-label, phase II study to investigate the efficacy and toxicities of total neoadjuvant therapy in patients with middle or lower rectal cancer.
This study is planned to start after the approval by IRB, enroll patients for 2 years, and follow the clinical outcome for another 5 years.
It will be conducted at National Cheng Kung University Hospital.
Forty-two subjects will be enrolled.
Patients who have newly diagnosed stage II or III, middle or low rectal adenocarcinoma will be recruited to receive the TNT treatment.
The TNT includes the short-course radiotherapy (5×5 Gy over a maximum of 8 days)) followed by chemotherapy with the regimen of mFOLFOX6 for total 9 cycles
Study Type
Interventional
Enrollment (Estimated)
42
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Yu-Min Yeh, MD
- Phone Number: 6550 +886 353535
- Email: i5485111@gmail.com
Study Locations
-
-
-
Tainan, Taiwan, 704
- Recruiting
- National Cheng Kung University Hospital
-
Principal Investigator:
- Yu-Min Yeh, MD
-
Contact:
- Yu-Min Yeh, MD
- Phone Number: 4289 886-6-2353535
- Email: i5485111@gmail.com
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Histologically confirmed diagnosis of adenocarcinoma of the rectum;
- Tumors located at mid or low rectum (distal extension less than 10 cm from the anal verge);
- Clinical stage II or III (T3/4 and/or N+; no distant metastasis);
- No prior chemotherapy, radiotherapy or surgery for rectal cancer;
- Age ≥20;
- ECOG 0-1;
- Adequate organ function, including followings:
ANC ≥1,500/μL; Hb ≥8.0 gm/dL; Platelet 100,000/mm3; Total bilirubin ≤1.5x upper normal limit; AST ≤3x upper normal limit; ALT ≤3x upper normal limit; Creatinine ≤1.5x upper normal limit;
- Ability to understand and the willingness to sing a written informed consent.
Exclusion criteria
- Recurrent rectal cancer;
- Patients who have concomitant malignancies, except for adequately treated basal cell carcinoma of the skin or in situ carcinoma of the cervix. Subjects who have prior malignancies and have been disease-free for more than 5 years can be enrolled;
- Patients who have received prior pelvic radiotherapy;
- Patients with active infection requiring intravenous antibiotic treatment;
- Patients with a history of any arterial thrombotic event within the past 6 months, including unstable angina, myocardial infarction (MI) or cerebrovascular accident (CVA), New York Hear Association (NYHA) grade II or greater congestive heart failure, or uncontrolled cardiac arrhythmia;
- Patients with any other concurrent medical or psychiatric condition or disease which, in the investigator's judgement, would make them inappropriate candidates for entry into this study;
- Women who are pregnant or breastfeeding. Women of childbearing potential who are unwilling or unable to use an acceptable method of birth control to avoid pregnancy for the entire study period;
- Patients receiving other anticancer or experimental therapy;
- Known DPD deficiency or hypersensitivity to oxaliplatin;
- Any contraindications to MRI.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental arm
The total neoadjuvant therapy with the short-course radiotherapy (5×5 Gy over a maximum of 8 days) followed by chemotherapy with mFOLFOX6 for 9 cycles will be administered.
|
Short-course radiotherapy, 5×5 Gy.
Other Names:
Oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, infusinal 5-fluorouracil 2400 mg/m2 every 2 weeks, for 9 cycles
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Complete response (CR) rate
Time Frame: The response will be assessed at the period of 2 to 4 weeks after the completion of total neoadjuvant chemotherapy
|
The percentage of patients who achieve a complete response
|
The response will be assessed at the period of 2 to 4 weeks after the completion of total neoadjuvant chemotherapy
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
R0 resection rate
Time Frame: The R0 resection rate will be assessed at the period of 2 to 4 weeks after completion of the total neoadjuvant chemotherapy
|
The percentage of patients who receive the surgery of total neoadjuvant therapy and achieve R0 resection
|
The R0 resection rate will be assessed at the period of 2 to 4 weeks after completion of the total neoadjuvant chemotherapy
|
Response rate
Time Frame: The response will be assessed at the period of 2 to 4 weeks after the completion of total neoadjuvant chemotherapy
|
The percentage of patients who achieve a complete response or partial response
|
The response will be assessed at the period of 2 to 4 weeks after the completion of total neoadjuvant chemotherapy
|
Loco-regional failure rate
Time Frame: The loco-regional failure will be assessed from the date of surgical resection until the first documented local recurrence, up to 84 months
|
The percentage of patients who develop local recurrence after surgery
|
The loco-regional failure will be assessed from the date of surgical resection until the first documented local recurrence, up to 84 months
|
Rate of distant metastasis
Time Frame: The distant metastasis will be assessed from the date of beginning short-course RT until the first documented distant metastasis, up to 84 months
|
The percentage of patients who develop distant metastasis
|
The distant metastasis will be assessed from the date of beginning short-course RT until the first documented distant metastasis, up to 84 months
|
Safety profiles
Time Frame: The safety profile will be assessed from the beginning of the short-course RT to the end of last cycle of FOLFOX chemotherapy, up to 24 weeks
|
The occurrence and severity of adverse events which develop during the treatment of total neoadjuvant therapy
|
The safety profile will be assessed from the beginning of the short-course RT to the end of last cycle of FOLFOX chemotherapy, up to 24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Yu-Min Yeh, MD, National Cheng-Kung University Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 16, 2023
Primary Completion (Estimated)
November 16, 2026
Study Completion (Estimated)
November 16, 2030
Study Registration Dates
First Submitted
November 27, 2023
First Submitted That Met QC Criteria
December 7, 2023
First Posted (Estimated)
December 8, 2023
Study Record Updates
Last Update Posted (Estimated)
December 8, 2023
Last Update Submitted That Met QC Criteria
December 7, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- B-BR-112-042
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rectal Cancer
-
Ohio State University Comprehensive Cancer CenterNovartis Pharmaceuticals; National Comprehensive Cancer NetworkCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Recurrent Rectal CancerUnited States
-
M.D. Anderson Cancer CenterRecruitingEvaluation of Quality of Life and Utilities Following Surgical Treatment of Stage I-IV Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Stage IV Rectal Cancer AJCC v8 | Stage IVA Rectal Cancer AJCC v8 | Stage IVB Rectal Cancer AJCC v8 | Stage IVC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage... and other conditionsUnited States
-
OHSU Knight Cancer InstituteNatera, Inc.RecruitingEstablishing a ctDNA Biomarker to Improve Organ Preserving Strategies in Patients With Rectal CancerStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8United States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)WithdrawnStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Rectal AdenocarcinomaUnited States
-
OHSU Knight Cancer InstituteOregon Health and Science University; Taiho Pharmaceutical Co., Ltd.RecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8United States
-
Jonsson Comprehensive Cancer CenterNatera, Inc.; The Joseph Drown FoundationRecruitingStage III Rectal Cancer AJCC v8 | Stage IIIA Rectal Cancer AJCC v8 | Stage IIIB Rectal Cancer AJCC v8 | Stage IIIC Rectal Cancer AJCC v8 | Rectal Adenocarcinoma | Stage IIA Rectal Cancer AJCC v8 | Stage IIB Rectal Cancer AJCC v8 | Stage II Rectal Cancer AJCC v8 | Stage IIC Rectal Cancer AJCC v8 | Locally...United States
-
Case Comprehensive Cancer CenterCompletedStage IIA Rectal Cancer | Stage IIB Rectal Cancer | Stage IIC Rectal Cancer | Stage IIIA Rectal Cancer | Stage IIIB Rectal Cancer | Stage IIIC Rectal Cancer | Stage IIIA Colon Cancer | Stage IIIB Colon Cancer | Stage IIIC Colon Cancer | Recurrent Colon Cancer | Recurrent Rectal Cancer | Stage IVA Colon Cancer | Stage IVA Rectal Cancer and other conditionsUnited States
-
National Cancer Institute (NCI)TerminatedMetastatic Rectal Adenocarcinoma | Rectal Adenocarcinoma | Stage III Rectal Cancer AJCC v7 | Stage IIIA Rectal Cancer AJCC v7 | Stage IIIB Rectal Cancer AJCC v7 | Stage IIIC Rectal Cancer AJCC v7 | Stage IV Rectal Cancer AJCC v7 | Stage IVA Rectal Cancer AJCC v7 | Stage IVB Rectal Cancer AJCC v7 | Locally...United States
-
City of Hope Medical CenterWithdrawnRecurrent Rectal Cancer | Stage I Rectal Cancer | Stage II Rectal Cancer | Stage III Rectal Cancer
Clinical Trials on Short-course radiotherapy
-
International Atomic Energy AgencyCompletedEsophageal CancerChina, Canada, Croatia, India, Pakistan, South Africa, Thailand
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompleted
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPalliative Care
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompleted
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompletedPalliative Care
-
IRCCS Azienda Ospedaliero-Universitaria di BolognaCompleted
-
Zhongnan HospitalUnknown
-
Wuhan Union Hospital, ChinaNot yet recruitingUnresectable Advanced Solid Tumors | Biliary Tract Tumors, Gastric Cancer, Small Cell Lung CancerChina
-
Maria Sklodowska-Curie National Research Institute...Unknown
-
Trans Tasman Radiation Oncology GroupAustralasian Gastro-Intestinal Trials Group; Colorectal Surgical Society of... and other collaboratorsCompletedAdenocarcinoma of RectumAustralia, New Zealand